Loading...
At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2015), held May 29 through June 2 in Chicago, specialists discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Associate Editor Robert Dreicer, MD, reviews key presentations on new prostate cancer therapies. All meeting abstracts can be viewed in the ASCO meeting library.
Last year's ASCO plenary presentation of the CHAARTED study provided compelling evidence of the benefit of adding docetaxel to standard androgen-deprivation therapy (ADT) for high-volume metastatic prostate can…